Overview

* Elevance Health Q3 2025 operating revenue rose 12% yr/yr to $50.1 bln

* Adjusted EPS for Q3 2025 beats analyst expectations

* Benefit expense ratio increased to 91.3%

Outlook

* Elevance Health ( ELV ) reaffirms FY 2025 adjusted EPS guidance of approximately $30.00

* Company focuses on advancing affordability and improving member experience

* Elevance Health ( ELV ) plans for sustainable growth and value creation in 2026

Result Drivers

* PREMIUM YIELDS - Higher premium yields in Health Benefits segment contributed to revenue growth

* MEDICARE ADVANTAGE GROWTH - Growth in Medicare Advantage membership supported revenue increase

* CAREYON ACQUISITIONS - Acquisitions in home health and pharmacy services boosted Carelon revenue

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $50.1

Operatin bln

g

Revenue

Q3 Beat $6.03 $4.93

Adjusted (20

EPS Analysts

)

Q3 EPS $5.32

Q3 91.30%

Benefit

Expense

Ratio

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 11 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the managed healthcare peer group is "buy"

* Wall Street's median 12-month price target for Elevance Health Inc ( ELV ) is $382.50, about 7.4% above its October 20 closing price of $354.07

* The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)